J Clin Invest.
Quantitative serum reactivity against RAFTK and C57(RBP-Jκ) measured using ELISA. Normal sera (n = 13), sera from CML patients (n = 12) receiving hydroxyurea, and pre-BMT sera from DLI responders (n = 13) demonstrate no reactivity to RAFTK or C57 (RBP-Jκ) compared with reactivity against GST negative control. One patient with CML demonstrated significant reactivity against RAFTK. All sera were diluted at 1:200.